We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SCOLR Pharma Extends Research Agreement with Consumer Products Company

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

SCOLR Pharma, Inc. has announced an extension of its research agreement with a global consumer products company to co-develop an application of its CDT® drug delivery technology.

Stephen J. Turner, SCOLR’s Vice President and Chief Technical Officer, stated “This extension is a positive indication of the progress we are making with our co-development partner on a novel application of our CDT drug delivery technology. We remain optimistic that if successful, a branded consumer product incorporating our technology could begin commercialization by 2009.”

SCOLR recently announced entering a development and licensing agreement with Dr. Reddy for a cardiopulmonary application of its CDT technology. SCOLR also continues its collaboration with Biocryst to development of an oral application of Biocryst’s peramivir, an anti-viral compound currently in clinical trials as potential intramuscular and intervenous treatments for seasonal and life-threatening influenza.

Under the terms of the agreement, SCOLR will receive a research fee. If the program is successful, it is anticipated that the parties would enter a global license agreement to allow for application of SCOLR’s technology.